Search the Newsreel

Ceribell appoints Thomas West and Sharon O’Keefe to its Board to boost brain monitoring tech adoption.

Ceribell, a medical technology company focused on neurological care, has appointed Thomas West and Sharon O’Keefe to its Board of Directors. These strategic appointments aim to accelerate the commercial scaling and adoption of Ceribell’s point-of-care brain monitoring platform within hospitals. The company's FDA-cleared AI-powered …

Ceribell to Participate in the Canaccord Genuity 46th Annual Growth Conference

Ceribell, Inc. (Nasdaq: CBLL), a medical technology company, announced that its CFO, Scott Blumberg, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference. The event is scheduled for Wednesday, August 12, 2026, at 6:00 a.m. PDT / 9:00 a.m. …

CeriBell Inc (CBLL) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of CeriBell Inc (CBLL), detailing its price momentum, support and resistance levels, and various technical indicators and moving averages. It highlights that CBLL's current price momentum score is 4.39, ranking it within the top half of its industry, …

Ceribell Expands Board of Directors with Appointments of Thomas West and Sharon O’Keefe

Ceribell, a medical technology company, announced the appointments of Thomas West and Sharon O’Keefe to its Board of Directors. West brings experience scaling medical technologies and led companies through significant acquisitions, while O’Keefe offers extensive leadership experience from major academic health systems. Their combined …

CeriBell Inc (CBLL) Financial Health: Profitability & Balance Sheet Analysis

CeriBell Inc (CBLL) currently holds a robust financial score of 7.30, placing it 93rd out of 199 companies in the Healthcare Equipment & Supplies industry. The company reported a 29.30% year-over-year increase in quarterly revenue to $26.49M, and a significant 54.47% increase in net …

Ceribell CFO to speak at Canaccord Genuity Growth Conference on Aug 12, 2026

Ceribell, a medical technology company focusing on neurological diagnostics, announced that its CFO, Scott Blumberg, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. This event, highlighting Ceribell's portable AI-powered EEG system, signifies the company's …

CBLL|CeriBell Inc|Price:17.735|Chg%:-0.095

CeriBell Inc. (CBLL) is a medical technology company specializing in the diagnosis and management of neurological conditions through its Ceribell System, an FDA-cleared point-of-care EEG platform. The system uses portable hardware and AI to rapidly diagnose and monitor patients for suspected seizure activity in …

CeriBell Inc (CBLL) Income Statement

This article provides the quarterly and annual income statements for CeriBell Inc (CBLL), offering detailed financial data such as total revenue, cost of revenue, operating expenses, and net income from FY2022Q1 through FY2026Q1. It also includes frequently asked questions about interpreting income statements and …

CeriBell Inc (CBLL) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of CeriBell Inc (CBLL), listing major shareholders and their proportions, including TPG Capital, Fidelity Management, and Longitude Capital. It also provides information on shareholder types, institutional holdings over several quarters, and recent shareholder activity with changes in holdings. …

CeriBell, Inc. Revenue Breakdown – NASDAQ:CBLL

CeriBell, Inc. (NASDAQ:CBLL) generated $89.06 million USD in revenue last year, with its Electroencephalography Recorders and Headbands segment contributing the most at $67.33 million USD. The vast majority of its revenue, $89.06 million USD, originated from the United States. This indicates a strong concentration …

CBLL|CeriBell Inc|Price:18.140|Chg%:+1.230

CeriBell Inc (CBLL) is a medical technology company focused on neurological conditions, trading at $18.14 with a 7.27% increase. Analysts have a "Strong Buy" rating with a target price of $26.86, indicating high growth potential despite market volatility. The company's fundamentals are strong, evidenced …

Ceribell to Report Second Quarter 2026 Financial Results on August 10, 2026

Ceribell, Inc. (Nasdaq: CBLL) announced it will release its second-quarter 2026 financial results after the market closes on Monday, August 10, 2026. The company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the …

CeriBell (FRA:W3H) Cyclically Adjusted PS Ratio : (As of Jul. 16, 2026)

This article discusses the Cyclically Adjusted PS Ratio for CeriBell (FRA:W3H) as of July 16, 2026. GuruFocus indicates that CeriBell does not have sufficient historical financial data (specifically, a history long enough to calculate Cyclically Adjusted Revenue per Share) to compute this metric. The …

CBLL Q1 2026 Earnings: EPS Misses Estimates Amid Pre-Revenue Phase, Stock Inches Higher - Earnings Call Q&A

CBLL Q1 2026 Earnings: EPS Misses Estimates Heavily, Stock Declines - Adjusted Earnings Analysis

CeriBell Inc. (CBLL) Q1 2026 Earnings: EPS Miss Weighs on Shares Amid Narrow Revenue Disclosure

CeriBell Inc. (CBLL) Q1 2026 Earnings: Wider-than-Expected Loss Weighs on Shares - Profit Cycle Analysis

CeriBell (CBLL) Q1 2026 Earnings Transcript

CeriBell, Inc. (CBLL) Reports Q1 Loss, Beats Revenue Estimates

CeriBell (CBLL) Earnings Date and Reports 2026 $CBLL

Should I buy CeriBell, Inc. (CBLL)